The strongest network in the Swiss healthcare sector.
We are team players who show courage and take responsibility. We are over 7,600 talented people from around 80 different countries who do great things for Switzerland every day.
On hand to help the whole of Switzerland.
The Galenica network with over 20 Business Units brings together the strongest partners from the Swiss healthcare sector and offers fully integrated solutions for end consumers and patients, as well as for pharmacies, drugstores, medical practices, hospitals, nursing homes, home care providers, wholesalers, pharmaceutical companies, health insurance funds and other partners. And we'd be happy to move on with you as well.
We support people at every stage of life on their journey towards health and well-being.
Anytime and anywhere in Switzerland.
“We do great things every day”
Prepared for what tomorrow may bring. From maintaining the densest pharmacy network in Switzerland to developing state-of-the-art e-health solutions
We provide top-notch services in the fields of pharmacy, healthcare, medicine, manufacturing, IT, logistics and consulting – perfectly harmonised and fully integrated to meet your individual needs.
What do our diverse network members have in common?
Our shared values.
E-prescription: Galenica rethinks healthcare.
Integrating the Documedis® e-prescription makes the medication process more efficient. Prescriptions are signed electronically, so there is no need to sign by hand or type prescriptions out. The information, including the signature, is all contained in the QR code. The QR code must be scanned in order to check the validity of the prescription and to be able to redeem it. Questions or misunderstandings arising from illegible paper prescriptions are a thing of the past. This allows patients to redeem their prescriptions from pharmacies more quickly.
Led by HCI Solutions, the Galenica network’s pilot phase was successfully completed in late 2022. The Documedis® e-prescription should become available to all medical and pharmaceutical specialists and patients within the next few months.